Hydantoin compounds, their preparation and pharmaceutical formulations containing them
申请人:Lilly Industries Limited
公开号:EP0005647A1
公开(公告)日:1979-11-28
Hydantoin compounds are described, having the following formula
wherein Ar is phenyl optionally substituted by up to three radicals selected
from the group comprising C1-6 alkoxy, halogen, 1,3-dioxol-2-yl, hydroxy C1-4 alkoxy C1-4 alkyl, phenyl, hydroxyl, nitrile, C1-4 haloalkyl, C1-4 alkyl, C2-4 alkenyloxy, C1-4 alkoxycarbonyl or phenoxy optionally substituted by C1-4 haloalkyl, C1-4 alkoxy or halogen;
or is thiophene optionally substituted by phenyl or by one or two C1-4 alkyl groups;
R' and R2 are independently hydrogen or taken together represent a chemical bond;
R3 is hydrogen, C1-6 alkyl or C2-4 alkenyl; and
R4 is C1-6 alkyl, C2-4 alkenyl, phenyl or benzyl;
provided that R3 cannot be hydrogen when Ar is unsubstituted phenyl and R4 is n-butyl.
The compounds are useful in the prophylactic treatment of asthma in mammals.
所述的海因化合物具有下式
其中 Ar 是苯基,可任选被最多三个基团取代,这三个基团选自
C1-6 烷氧基、卤素、1,3-二氧戊环-2-基、羟基 C1-4 烷氧基、C1-4 烷基、苯基、羟基、腈基、C1-4 卤代烷基、C1-4 烷基、C2-4 烯氧基、C1-4 烷氧羰基或任选被 C1-4 卤代烷基、C1-4 烷氧基或卤素取代的苯氧基;
或任选被苯基或一个或两个 C1-4 烷基取代的噻吩;
R' 和 R2 独立为氢或共同代表一个化学键;
R3 是氢、C1-6 烷基或 C2-4 烯基;以及
R4 是 C1-6 烷基、C2-4 烯基、苯基或苄基;
但当 Ar 为未取代苯基且 R4 为正丁基时,R3 不能为氢。
这些化合物可用于哺乳动物哮喘的预防性治疗。